SGX Pharmaceuticals Inc: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-18

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

SGX Pharmaceuticals's main focus is to discover, develop and commercialize products for the treatment of diseases in the therapeutic area of oncology. The company seeks to build a franchise of oncology products through its own internal efforts as well as partnering with other pharmaceutical companies to develop and commercialize innovative cancer therapeutics.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    SGX Pharmaceuticals has two programs in discovery stage, namely, JAK2 inhibitor and RAS inhibitor, for the treatment of myeloproliferative disorders and solid tumors respectively. SGX-523, which is in the preclinical stage, is an oral small molecule kinase inhibitor indicated for the treatment of solid tumors.

    SGX Pharmaceuticals derives its revenues mainly from collaboration, commercial agreement and grants received on various contractual agreements with pharmaceutical and biotechnology companies such as Novartis and Cystic Fibrosis Foundation Therapeutics, as well as government and other agencies. The company does not have any marketed product.

    SGX Pharmaceuticals's biggest contributor to sales growth out to 2010 will be collaboration and commercial agreements stream, which would be recognized in connection with the collaboration and commercial agreements with Novartis and Cystic Fibrosis Foundation Therapeutics.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: sgx sgxpharmaceuticalsuk pharmaceuticals sgx523 structure ras uk pharmaceutical inc pharma

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.